Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus

Abstract

AimsCanagliflozin, a sodium glucose co-transporter 2 inhibitor, has demonstrated glycemic improvements across studies of patients with type 2 diabetes mellitus (T2DM). The impact of canagliflozin on HbA1c lowering was assessed by baseline HbA1c and known duration of T2DM. MethodsThis post hoc analysis pooled data from patients with T2DM enrolled in four 26-week, placebo-controlled, Phase 3 studies of canagliflozin (N=2313). Change in HbA1c from baseline to Week 26 was assessed in the overall population and in subgroups by baseline HbA1c (<8.0%, 8.0%–<9.0%, and ≥9.0%) and known duration of T2DM (<5 years, 5–<10 years, and ≥10 years). ResultsRelative to placebo, canagliflozin 100 and 300mg provided greater HbA1c reductions in the overall population. Progressively larger placebo-subtracted reductions in HbA1c with canagliflozin 100 and 300mg were seen with increasing baseline HbA1c. HbA1c reductions were similar across subgroups based on known duration of T2DM. Both canagliflozin doses were generally well tolerated across subgroups, with a safety and tolerability profile consistent with that seen in Phase 3 studies. ConclusionsCanagliflozin provided glycemic improvements in patients with T2DM across a range of baseline HbA1c and known duration of T2DM.